Description
AC-262 (AC-262536)
AC-262536, often shortened to AC-262, is an investigational selective androgen receptor modulator (SARM). Early pharmacological research characterized it as an androgen-receptor ligand with partial agonist activity in experimental assays. It is not an approved medicine, and evidence supporting safety or effectiveness in humans is inadequate.
How It Works
AC-262536 interacts with androgen receptors, which regulate biological processes in androgen-responsive tissues. Early cell-based research investigated its receptor activity, but laboratory findings do not establish selective effects or favorable safety outcomes in humans.
POTENTIAL RESEARCH INTEREST
- Androgen-receptor pharmacology: Investigated for binding and activity at androgen receptors.
- Partial agonist activity: Examined in experimental receptor assays.
- Tissue-selectivity research: Relevant to broader studies of selective androgen receptor modulators.
- Preclinical characterization: Provides a candidate for investigating androgen-receptor signaling.
Side Effects and Safety
Human safety, long-term endocrine effects, and clinical efficacy have not been established. SARM-related concerns can include hormonal disruption, liver injury, and adverse lipid changes; the precise risks of AC-262 itself remain insufficiently characterized.
Dosage
No validated human-use dosage is established for AC-262536.
Handling & Safety
Confirm the chemical identity and analytical documentation. Do not treat product-market claims as evidence of safety or performance.
Where to Find AC-262
IML provides research information and links to independent suppliers. The selected supplier handles product sales and fulfillment.
Affiliate Disclosure: IronMountainLabz does not sell or ship AC-262. Links on this page may direct readers to independent suppliers through affiliate links.
